(MedPage Today) — The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday.
Approval stipulates use in metastatic hormone-sensitive prostate…
(MedPage Today) — The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday.
Approval stipulates use in metastatic hormone-sensitive prostate…